Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF

Journal of Immunology

Volumn 177, Issue 4, 2006, Pages 2671-2680

  Jacob, Chaim O ^a   Pricop, Luminita ^b   Putterman, Chaim ^c   Koss, Michael N ^a   Liu, Yi ^b   Kollaros, Maria ^c   Bixler, Sarah A ^d   Ambrose, Christine M ^d   Scott, Martin L ^d   Stohl, William ^a,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d BIOGEN   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD5 ANTIGEN; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; KIDNEY ANTIBODY; PROTEIN BAFF; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SURVIVAL; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE OVEREXPRESSION; GENETIC MANIPULATION; GERMINAL CENTER; GLOMERULONEPHRITIS; GLOMERULOPATHY; IMMUNOGLOBULIN DEPOSITION; IMMUNOGLOBULIN PRODUCTION; INBRED STRAIN; KIDNEY DISEASE; MORTALITY; MOUSE; MOUSE STRAIN; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEINURIA; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 33746890544     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.4.2671     Document Type: Article

References (80)

1. Schneider, P., F. MacKay, V. Steiner, K. Hofmann, J.-L. Bodmer, N. Holler, C. Ambrose, P. Lawton, S. Bixler, H. Acha-Orbea, et al. 1999. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J. Exp. Med. 189: 1747-1756.
2. Moore, P. A., O. Belvedere, A. Orr, K. Pieri, D. W. LaFleur, P. Feng, D. Soppet, M. Charters, R. Gentz, D. Parmelee, et al. 1999. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
3. Shu, H.-B., W.-H. Hu, and H. Johnson. 1999. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J. Leukocyte Biol. 65: 680-683.
4. 2-terminal kinase. J. Biol. Chem. 274: 15978-15981.
5. Tribouley, C., M. Wallroth, V. Chan, X. Paliard, E. Fang, G. Lamson, D. Pot, J. Escobedo, and L. T. Williams. 1999. Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol. Chem. 380: 1443-1447.
6. Gross, J. A., J. Johnston, S. Mudri, R. Enselman, S. R. Dillon, K. Madden, W. Xu, J. Parrish-Novak, D. Foster, C. Lofton-Day, et al. 2000. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999.
7. Nardelli, B., O. Belvedere, V. Roschke, P. A. Moore, H. S. Olsen, T. S. Migone, S. Sosnovtseva, J. A. Carrell, P. Feng, J. G. Giri, et al. 2001. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198-194.
8. Scapini, P., B. Nardelli, G. Nadali, F. Calzetti, G. Pizzolo, C. Montecucco, and M. A. Cassatella. 2003. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J. Exp. Med. 197: 297-302.
9. Gorelik, L., K. Gilbride, M. Dobles, S. L. Kalled, D. Zandman, and M. L. Scott. 2003. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J. Exp. Med. 198: 937-945.
10. Huard, B., L. Arlettaz, C. Ambrose, V. Kindler, D. Mauri, E. Roosnek, J. Tschopp, P. Schneider, and L. E. French. 2004. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int. Immunol. 16: 467-475.
11. Thompson, J. S., P. Schneider, S. L. Kalled, L. Wang, E. A. Lefevre, T. G. Cachero, F. MacKay, S. A. Bixler, M. Zafari, Z.-Y. Liu, et al. 2000. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J. Exp. Med. 192: 129-135.
12. Do, R. K. G., E. Hatada, H. Lee, M. R. Tourigny, D. Hilbert, and S. Chen-Kiang. 2000. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 192: 953-964.
13. Batten, M., J. Groom, T. G. Cachero, F. Qian, P. Schneider, J. Tschopp, J. L. Browning, and F. Mackay. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192: 1453-1465.
14. Harless, S. M., V. M. Lentz, A. P. Sah, B. L. Hsu, K. Clise-Dwyer, D. M. Hilbert, C. E. Hayes, and M. P. Cancro. 2001. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr. Biol. 11: 1986-1989.
15. Hsu, B. L., S. M. Harless, R. C. Lindsley, D. M. Hilbert, and M. P. Cancro. 2002. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J. Immunol. 168: 5993-5996.
16. Avery, D. T., S. L. Kalled, J. I. Ellyard, C. Ambrose, S. A. Bixler, M. Thien, R. Brink, F. Mackay, P. D. Hodgkin, and S. G. Tangye. 2003. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J. Clin. Invest. 112: 286-297.
17. Hatada, E. N., R. K. G. Do, A. Orlofsky, H.-C. Liou, M. Prystowsky, I. C. M. MacLennan, J. Caamano, and S. Chen-Kiang. 2003. NF-κB1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-κB2 p100 to p52 in quiescent mature B cells. J. Immunol. 171: 761-768.
18. Mackay, F., S. A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and J. L. Browning. 1999. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190: 1697-1710.
19. Khare, S. D., I. Sarosi, X.-Z. Xia, S. McCabe, K. Miner, I. Solovyev, N. Hawkins, M. Kelley, D. Chang, G. Van, et al. 2000. Severe B cell hyperplasia and autoimmune disease in TALL-I transgenic mice. Proc. Natl. Acad. Sci. USA 97: 3370-3375.
20. Stohl, W., D. Xu, K. S. Kim, M. N. Koss, T. N. Jorgensen, B. Deocharan, T. E. Metzger, S. A. Bixler, Y. S. Hong, C. M. Ambrose, et al. 2005. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 52: 2080-2091.
21. Zhang, J., V. Roschke, K. P. Baker, Z. Wang, G. S. Alarcón, B. J. Fessler, H. Bastian, R. P. Kimberly, and T. Zhou. 2001. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol. 166: 6-10.
22. Cheema, G. S., V. Roschke, D. M. Hilbert, and W. Stohl. 2001. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44: 1313-1319.
23. Stohl, W., S. Metyas, S.-M. Tan, G. S. Cheema, B. Oamar, D. Xu, V. Roschke, Y. Wu, K. P. Baker, and D. M. Hilbert. 2003. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48: 3475-3486.
24. Petri, M., W. Stohl, W. Chatham, W. McCune, M. Chevrier, Y.-L. Shen, J. Zhong, A. Orr, L. Hall, and W. Freimuth. 2004. Association of BLyS™ with measures of disease activity in a prospective SLE observational study. Arthritis Rheum. 50: S603.
25. Collins, C. E., A. L. Gavin, T.-S. Migone, D. M. Hilbert, D. Nemazee, and W. Stohl. 2006. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res. Ther. 8: R6.
26. Gross, J. A., S. R. Dillon, S. Mudri, J. Johnston, A. Littau, R. Roque, M. Rixon, O. Schou, K. P. Foley, H. Haugen, et al. 2001. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15: 289-302.
27. Schiemann, B., J. L. Gommerman, K. Vora, T. G. Cachero, S. Shulga-Morskaya, M. Dobles, E. Frew, and M. L. Scott. 2001. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2111-2114.
28. Kayagaki, N., M. Yan, D. Seshasayee, H. Wang, W. Lee, D. M. French, I. S. Grewal, A. G. Cochran, N. C. Gordon, J. Yin, et al. 2002. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity 10: 515-524.
29. Ramanujam, M., X. Wang, W. Huang, L. Schiffer, C. Grimaldi, A. Akkerman, B. Diamond, M. P. Madaio, and A. Davidson. 2004. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J. Immunol. 173: 3524-3534.
30. Ramanujam, M., X. Wang, W. Huang, Z. Liu, L. Schiffer, H. Tao, D. Frank, J. Rice, B. Diamond, K. O. A. Yu, et al. 2006. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J. Clin. Invest. 116: 724-734.
31. Lesley, R., Y. Xu, S. L. Kalled, D. M. Hess, S. R. Schwab, H.-B. Shu, and J. G. Cyster. 2004. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20: 441-453.
32. Thien, M., T. G. Phan, S. Gardam, M. Amesbury, A. Basten, F. Mackay, and R. Brink. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785-798.
33. z homozygous inbred strains of mice derived from New Zealand Black and New Zealand White mice: origins and initial characterization. Lab. Invest. 68: 419-426.
34. Morel, L., Y. Yu, K. R. Blenman, R. A. Caldwell, and E. K. Wakeland. 1996. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm. Genome 7: 335-339.
35. Markel, P., P. Shu, C. Ebeling, G. A. Carlson, D. L. Nagle, J. S. Smutko, and K. J. Moore. 1997. Theoretical and empirical issue for marker-assisted breeding of congenic mouse strains. Nat. Genet. 17: 280-284.
36. Waters, S. T., S. M. Fu, F. Gaskin, U. S. Deshmukh, S.-S. J. Sung, C. C. Kannapell, K. S. K. Tung, S. B. McEwen, and M. DcDuffie. 2001. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin. Immunol. 100: 372-383.
37. Stohl, W., D. Xu, K. S. Kim, C. S. David, and J. P. Allison. 2004. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int. Immunol. 16: 895-904.
38. Stohl, W., D. N. Posnett, and N. Chiorazzi. 1987. Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies. J. Immunol. 138: 1667-1673.
39. Gronowicz, E., A. Coutinho, and F. Melchers. 1976. A plaque assay for all cells secreting Ig of a given type or class. Eur. J. Immunol. 6: 588-590.
40. Beger, E., B. Deocharan, M. Edelman, B. Erblich, Y. Gu, and C. Putterman. 2002. A peptide DNA surrogate accelerates autoimmune manifestations and nephritis in lupus-prone mice. J. Immunol. 168: 3617-3626.
41. Deocharan, B., P. Marambio, M. Edelman, and C. Putterman. 2003. Differential effects of interleukin-4 in peptide induced autoimmunity. Clin. Immunol. 108: 80-88.
42. Gorelik, L., A. H. Cutler, G. Thill, S. D. Miklasz, D. E. Shea, C. Ambrose, S. A. Bixler, L. Su, M. L. Scott, and S. L. Kalled. 2004. Cutting edge: BAFF regulates CD2I/35 and CD23 expression independent of its B cell survival function. J. Immunol. 172: 762-766.
43. Vora, K. A., L. C. Wang, S. P. Rao, Z.-Y. Liu, G. R. Majeau, A. H. Cutler, P. S. Hochman, M. L. Scott, and S. L. Kalled. 2003. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J. Immunol. 171: 547-551.
44. Rahman, Z. S. M., S. P. Rao, S. L. Kalled, and T. Manser. 2003. Normal induction but attenuated progression of geminal center responses in BAFF and BAFF-R signaling-deficient mice. J. Exp. Med. 198: 1157-1169.
45. Berland, R., and H. H. Wortis. 2002. Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol. 20: 253-300.
46. Wither, J. E., C. Loh, G. Lajoie, S. Heinrichs, Y.-C. Cai, G. Bonventi, and R. MacLeod. 2005. Colocalization of expansion of the splenic marginal zone population with abnormal B cell activation and autoantibody production in B6 mice with an introgressed New Zealand Black chromosome 13 interval. J. Immunol. 175: 4309-4319.
47. Tumang, J. R., W. D. Hastings, C. Bai, and T. L. Rothstein. 2004. Peritoneal and splenic B-1 cells are separable by phenotypic, functional, and transcriptomic characteristics. Eur. J. Immunol. 34: 2158-2167.
48. Jacob, C. O., S. Zang, L. Li, V. Ciobanu, F. Quismorio, A. Mazutani, M. Satoh, and M. Koss. 2003. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand Mixed 2328 mice. J. Immunol. 171: 1564-1571.
49. Laabi, Y., M.-P. Gras, J.-C. Brouet, R. Berger, C.-J. Larsen, and A. Tsapis. 1994. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 22: 1147-1154.
50. von Bülow, G.-U., and R. J. Bran. 1997. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278: 138-141.
51. Thompson, J. S., S. A. Bixler, F. Qian, K. Vora, M. L. Scott, T. G. Cachero, C. Hession, P. Schneider, I. D. Sizing, C. Mullen, et al. 2001. BAFF-R, a novel TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
52. Yan, M., J. R. Brady, B. Chan, W. P. Lee, B. Hsu, S. Harless, M. Cancro, I. S. Grewal, and V. M. Dixit. 2001. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11: 1547-1552.
53. Ye, Q., L. Wang, A. D. Wells, R. Tao, R. Han, A. Davidson, M. L. Scott, and W. W. Hancock. 2004. BAFF binding to T cell-expressed BAFF-R costimulates T cell proliferation and alloresponses. Eur. J. Immunol. 34: 2750-2759.
54. Ng, L. G., A. P. R. Sutherland, R. Newton, F. Qian, T. G. Cachero, M. L. Scott, J. S. Thompson, J. Wheway, T. Chtanova, J. Groom, et al. 2004. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J. Immunol. 173: 807-817.
55. Huard, B., P. Schneider, D. Mauri, J. Tschopp, and L. E. French. 2001. T cell costimulation by the TNF ligand BAFF. J. Immunol. 167: 6225-6231.
56. Balázs, M., F. Martin, T. Zhou, and J. F. Kearney. 2002. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17: 341-352.
57. L gene expression restored splenic B lymphocyte development in BAFF-R mutant mice. J. Immunol. 170: 4593-4600.
58. Tardivel, A., A. Tinel, S. Lens, Q.-G. Steiner, E. Sauberli, A. Wilson, F. Mackay, A. G. Rolink, F. Beermann, J. Tschopp, et al. 2004. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur. J. Immunol. 34: 509-518.
59. Sasaki, Y., S. Casola, J. L. Kutok, K. Rajewski, and M. Schmidt-Supprian. 2004. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J. Immunol. 173: 2245-2252.
60. Rahman, Z. A. M., and T. Manser. 2004. B cells expressing Bcl-2 and a signaling-impaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J. Immunol. 173: 6179-6188.
61. Marsters, S. A., M. Yan, R. M. Pitti, P. E. Haas, V. M. Dixit, and A. Ashkenazi. 2000. Interaction of the TNF homologues BLyS and APRIL with the receptor homologues BCMA and TACI. Curr. Biol. 10: 785-788.
62. Yu, G., T. Boone, J. Delaney, N. Hawkins, M. Kelley, M. Ramakrishnan, S. McCabe, W.-R Qiu, M. Kornuc, X.-Z. Xia, et al. 2000. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat. Immunol. 1: 252-256.
63. Wu, Y., D. Bressette, J. A. Carrell, T. Kaufman, P. Feng, K. Taylor, Y. Gan, Y. H. Cho, A. D. Garcia, E. Gollatz, et al. 2000. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J. Biol. Chem. 275: 35478-35485.
64. Rennert, P., P. Schneider, T. G. Cachero, J. Thompson, L. Trabach, S. Hertig, N. Holler, F. Qian, C. Mullen, K. Strauch, et al. 2000. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192: 1677-1683.
65. O'Connor, B. P., V. S. Raman, L. D. Erickson, W. J. Cook, L. K. Weaver, C. Ahonen, L.-L. Lin, G. T. Mantchev, R. J. Bram, and R. J. Noelle. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199: 91-97.
66. Yang, M., H. Hase, D. Legarda-Addison, L. Varughese, B. Seed, and A. T. Ting. 2005. BCMA, the receptor for APRIL and BAFF, induces antigen presentation in B cells. J. Immunol. 175: 2814-2824.
67. von Bülow, G.-U., J. M. van Deursen, and R. J. Bram. 2001. Regulation of the T-independent humoral response by TACI. Immunity 14: 573-574.
68. Yan, M., H. Wang, B. Chan, M. Roose-Girma, S. Erickson, T. Baker, D. Tumas, I. S. Grewal, and V. M. Dixit. 2001. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2: 638-643.
69. Castigli, E., S. A. Wilson, S. Scott, F. Dedeoglu, S. Xu, K.-P. Lam, R. J. Bram, H. Jabara, and R. S. Geha. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201: 35-34.
70. Litinskiy, M. B., B. Nardelli, D. M. Hilbert, B. He, A. Schaffer, P. Casali, and A. Cerutti. 2002. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat. Immunol. 3: 822-829.
71. Castigli, E., S. Scott, F. Dedeoglu, P. Bryce, H. Jabara, A. K. Bhan, E. Migozuchi, and R. S. Geha. 2004. Impaired IgA class switching in APRIL-deficient mice. Proc. Natl. Acad. Sci. USA 101: 3903-3908.
72. Stein, J. V., M. López-Fraga, F. A. Elustondo, C. E. Carvalho-Pinto, D. Rodríguez, R. Gómez-Caro, J. de Jong, C. Martínez-A, J. P. Medema, and M. Hahne. 2002. APRIL modulates B and T cell immunity. J. Clin. Invest. 109: 1587-1598.
73. He, B., N. Raab-Traub, P. Casali, and A. Cerutti. 2003. EBV-encoded latent membrane protein I cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J. Immunol. 171: 5215-5224.
74. Yamada, T., K. Zhang, A. Yamada, D. Zhu, and A. Saxon. 2005. B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am. J. Respir. Cell Mol. Biol. 32: 388-394.
75. Sutherland, A. P. R., L. G. Ng, C. A. Fletcher, B. Shum, R. A. Newton, S. T. Grey, M. S. Rolph, F. Mackay, and C. R. Mackay. 2005. BAFF augments certain Th1-associated inflammatory responses. J. Immunol. 174: 5537-5544.
76. Chan, O., and M. J. Shlomchik. 1998. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160: 51-59.
77. Shlomchik, M. J., M. P. Madaio, D. Ni, M. Trounstein, and D. Huszar. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180: 1295-1306.
78. Chan, O. T. M., L. G. Hannum, A. M. Haberman, M. P. Madaio, and M. J. Shlomchik. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189: 1639-1647.
79. Baker, K. P., B. M. Edwards, S. H. Main, G. H. Choi, R. E. Wager, W. G. Halpern, P. B. Lappin, T. Riccobene, D. Abramian, L. Sekut, et al. 2003. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48: 3253-3265.
80. Furie, R., W. Stohl, E. Ginzler, M. Becker, N. Mishra, W. Chatham, J. T. Merrill, A. Weinstein, W. J. McCune, J. Zhong, et al. 2003. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of Lymphostat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum. 48: S377.